Mucosal and systemic anti-GAG immunity induced by neonatal immunization with HIV LAMP/gag DNA vaccine in mice

Imagem de Miniatura
Arquivos
art_GOLDONI_Mucosal_and_systemic_antiGAG_immunity_induced_by_neonatal_2011.PDF (680.37 KB)
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2011
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER GMBH, URBAN & FISCHER VERLAG
Autores
GOLDONI, Adriana Leticia
MACIEL JR., Milton
PIUBELLI, Orlando
MELO, Andrea
MARQUES, Ernesto Torres
AUGUST, Joseph Thomas
Citação
IMMUNOBIOLOGY, v.216, n.4, p.505-512, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Vaccines capable of inducing mucosal immunity in early postnatal life until adulthood, protecting early sexual initiation, should be considered as strategies to vaccination against HIV. The HIV-1 GAG protein as a chimera with the lysosome-associated membrane protein (LAMP/gag), encoded by a DNA vaccine, is targeted to the endosomal/lysosomal compartment that contains class II MHC molecules and has been shown to be immunogenic in adult mice. Assuming that one such strategy could help to overcome the immunological immaturity in the early postnatal period, we have evaluated the systemic and mucosal immunogenicity of LAMP/gag immunization in neonatal mice. Intranasal immunization with LAMP/gag vaccine induced higher levels of sIgA and IgG anti-GAG antibodies in intestinal washes than did the gag vaccine. The combination of ID injections and the IN protocol with the chimeric vaccine promoted the increase of Ab levels in sera. Both vaccines induced splenic IFN-gamma- secreting cells against GAG peptide pools, as well as in vivo cytotoxic T lymphocyte (CTL) function, and increased the percentage of CD8+ T cells to the immunodominant class I peptide in gut and spleen. However, only the chimeric vaccine was able to enhance Th1/Th2 cytokine secretion in response to class II GAG peptide and to enhance IL-4-secreting cells against GAG peptides and p24 protein stimuli. Long-lasting humoral and cellular responses were detected until adult age, following neonatal immunization with the chimeric vaccine. The LAMP/gag vaccination was able to induce potent GAG-specific T and B cell immune responses in early life which are essential to elicit sustained and long-lasting mucosal and systemic humoral response.
Palavras-chave
DNA vaccines, HIV, Mice, Mucosal, Neonates
URI
https://observatorio.fm.usp.br/handle/OPI/23507
Referências
  1. Adkins B, 1999, IMMUNOL TODAY, V20, P330, DOI 10.1016/S0167-5699(99)01473-5
  2. Cazac BB, 2000, IMMUNITY, V13, P443, DOI 10.1016/S1074-7613(00)00044-3
  3. Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617
  4. Rollman E, 2004, GENE THER, V11, P1146, DOI 10.1038/sj.gt.3302275
  5. Huber S, 2004, J IMMUNOL, V173, P6526
  6. Lambert AA, 2008, BLOOD, V112, P1299, DOI 10.1182/blood-2008-01-136473
  7. Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7
  8. Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
  9. Kraynyak KA, 2010, VACCINE, V28, P1942, DOI 10.1016/j.vaccine.2009.10.095
  10. Grossman Z, 2006, NAT MED, V12, P289, DOI 10.1038/nm1380
  11. Arruda LB, 2006, J IMMUNOL, V177, P2265
  12. Kojima Y, 2002, VACCINE, V20, P2857, DOI 10.1016/S0264-410X(02)00238-4
  13. Jiang JQ, 2005, J VIROL, V79, P393, DOI 10.1128/JVI.79.1.393-400.2005
  14. Ruff AL, 1997, J BIOL CHEM, V272, P8671
  15. Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196
  16. Gerdts V, 2000, NAT MED, V6, P929
  17. de Witte L, 2007, P NATL ACAD SCI USA, V104, P19464, DOI 10.1073/pnas.0703747104
  18. Bessis N, 2004, GENE THER, V11, pS10, DOI 10.1038/sj.gt.3302364
  19. ROWELL JF, 1995, J IMMUNOL, V155, P1818
  20. Arthos J, 2008, NAT IMMUNOL, V9, P301, DOI 10.1038/ni1566
  21. Geijtenbeek TBH, 2003, CURR TOP MICROBIOL, V276, P31
  22. Neurath MF, 2002, NAT MED, V8, P567, DOI 10.1038/nm0602-567
  23. Adkins B, 2004, NAT REV IMMUNOL, V4, P553, DOI 10.1038/nri1394
  24. Brave A, 2008, VACCINE, V26, P5075, DOI 10.1016/j.vaccine.2008.03.066
  25. Chikhlikar P, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000135
  26. Dadaglio G, 2002, J IMMUNOL, V168, P2219
  27. Dale CJ, 2004, VACCINE, V23, P188, DOI 10.1016/j.vaccine.2004.05.024
  28. De Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x
  29. de Brito CA, 2009, IMMUNOTHERAPY, V1, P883, DOI [10.2217/imt.09.38, 10.2217/IMT.09.38]
  30. Deml L, 1999, CLIN CHEM LAB MED, V37, P199, DOI 10.1515/CCLM.1999.037
  31. Gouws E, 2008, AIDS, V22, pS5, DOI 10.1097/01.aids.0000341773.86500.9d
  32. *UNAIDS, 2008, REP GLOB AIDS EP, P1
  33. Valentin A, 2009, VACCINE, V27, P4840, DOI 10.1016/j.vaccine.2009.05.093
  34. Xiang ZQ, 2003, J IMMUNOL, V171, P4287

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/56